Infectious Disease Clinical Trials Update: Week 25, 2026

Published June 19, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years

This Phase 3 trial is exploring a new varicella vaccine regimen for children aged 12 months to 12 years to check its safety and ability to trigger immune protection. If successful, it could offer parents and healthcare providers additional vaccine options to help protect children from chickenpox. The study includes two doses given three months apart and plans to enroll about 780 children across multiple countries.

Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine

This Phase 3 study is testing the safety and immune response of a new COVID-19 vaccine called VYD2311, both alone and when given together with another COVID-19 vaccine. The trial is recruiting healthy adults in the United States who have not been vaccinated or infected before. If the vaccine works well and is safe, it may provide an additional option for COVID-19 vaccination that could improve protection or reduce side effects.

A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF

This trial is testing an RSV vaccine named RSVpreF in adults with respiratory syncytial virus infection to see if it is safe and can boost immune defense. RSV can cause serious lung infections, especially in older adults, so a successful vaccine might reduce illness severity and hospital visits. The study is recruiting 540 participants in India.

Evaluation of Quickly Diagnostic Saliva Tests for SARS-CoV-2

This study tested a new, easy-to-use saliva test for detecting COVID-19 infection in over 600 people in France. Unlike traditional nasal swabs, this saliva test is non-invasive and could make screening for COVID-19 faster and more comfortable. Results from this study will help improve how COVID-19 testing is done, potentially making it easier to identify cases earlier and reduce spread.

Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study

This Phase 2 study evaluated new antibody treatments designed to prevent COVID-19 in people with weakened immune systems. The study included thousands of participants across many countries and has now finished. These treatments could offer safer and more effective protection options for those who do not respond well to vaccines.

This week saw important progress in vaccines and tests for COVID-19, RSV, and chickenpox, as well as new prevention options for people with immune challenges. These studies bring hope for improved ways to prevent and detect infections in diverse patient groups. TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.